Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-19T20:53:25.908Z Has data issue: false hasContentIssue false
  • English
  • Français

Economic consequences of alternative medication strategies in first episode non-affective psychosis

Published online by Cambridge University Press:  05 April 2007

A.D. Stant ,
E.M. TenVergert ,
L. Wunderink ,
F.J. Nienhuis  and
D. Wiersma
A.D. Stant*
Affiliation:
Office for Medical Technology Assessment, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700RB Groningen, The Netherlands
E.M. TenVergert
Affiliation:
Office for Medical Technology Assessment, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700RB Groningen, The Netherlands
L. Wunderink
Affiliation:
Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands
F.J. Nienhuis
Affiliation:
Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands
D. Wiersma
Affiliation:
Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands
*
∗Corresponding author. Tel.: +31 50 361 2152; fax: +31 50 361 1738. E-mail addresses: [email protected] (A.D. Stant), e.m.ten.vergert@ mta.umcg.nl (E.M. TenVergert), [email protected] (L. Wunderink), [email protected] (F.J. Nienhuis), d.wiersma@acggn. umcg.nl (D. Wiersma).
Get access

Abstract

Background

Maintenance treatment appears to be successful in preventing relapses in first episode psychosis, but is also associated with side effects. Guided discontinuation strategy is a less intrusive intervention, but may lead to more relapses. In the current economic evaluation, costs and health outcomes of discontinuation strategy will be compared with the results of maintenance treatment in patients with remitted first episode psychosis.

Method

The study was designed as a randomised clinical trial. In total 128 patients were prospectively followed for 18 months after six months of stable remission. The economic evaluation was conducted from a societal perspective. Quality-adjusted life years (QALYs) were used as primary health outcome in the economic evaluation. Relapse rates were assessed in addition to various other secondary outcomes.

Results

There were no relevant differences in mean costs between groups during the study. Total costs were largely influenced by costs related to admissions to psychiatric hospitals. No differences between groups were found for QALY results.

Conclusions

There were no indications that either of the examined interventions is superior to the other in terms of costs or QALY results. Additional results indicated that the relapse rate in discontinuation strategy was twice as high, but without an increase in hospital admissions or negative consequences on other clinical outcomes. For a minority of remitted first episode patients, guided discontinuation strategy may offer a feasible alternative to maintenance treatment.

Keywords

First episode psychosisAntipsychoticsMaintenance treatmentGuided discontinuationCostEconomic evaluation
Type
Original article
Information
European Psychiatry , Volume 22 , Issue 6 , September 2007 , pp. 347 - 353
Copyright
Copyright © Elsevier Masson SAS 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (APA) Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington, DC: APA; 2004.Google Scholar
Bosveld-van Haandel, L.J., Slooff, C.J., van den Bosch, R.J.Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 2001;103:335–346.CrossRefGoogle ScholarPubMed
Carpenter, W.T., Hanlon, T.E., Heinrichs, D.W., Summerfelt, A.T., Kirkpatrick, B., Levine, J.et al.Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138–1148.Google ScholarPubMed
Carr, V.J., Lewin, T.J., Neil, A.L., Halpin, S.A., Holmes, S.Premorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychoses. Br J Psychiatry 2004;184:517–525.CrossRefGoogle ScholarPubMed
Dolan, P.Modeling valuations for EuroQol health states. Med Care 1997;35:1095–1108.CrossRefGoogle ScholarPubMed
Drummond, M.F., O'Brien, B.J., Stoddart, G.L., Torrance, G.W.Methods for the economic evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997.Google Scholar
Efron, B., Tibshirani, R.J.An introduction to the bootstrap. New York: Chapman & Hall; 1993.CrossRefGoogle Scholar
EuroQol Group, EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.Google Scholar
Henderson, D.C., Cagliero, E., Copeland, P.M., Borba, C.P., Evins, E., Hayden, D.et al.Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19–28.CrossRefGoogle ScholarPubMed
Herz, M.I., Glazer, W.M., Mostert, M.A., Sheard, M.A., Szymanski, H.V., Hafez, H.et al.Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991;48:333–339.CrossRefGoogle ScholarPubMed
Jakob-Tacken, K.H.M., Koopmanschap, M.A., Meerding, W.J., Severens, J.L.Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. Health Econ 2005;14:435–443.CrossRefGoogle Scholar
Kapur, S., Remington, G.Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503–517.CrossRefGoogle ScholarPubMed
Knapp, M.Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand 2000;102(Suppl. 407):15–18.CrossRefGoogle Scholar
Knapp, M., Chisholm, D., Leese, M., Amaddeo, F., Tansella, M., Schene, A.et al.Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON Study. Acta Psychiatr Scand 2002;105:42–54.CrossRefGoogle ScholarPubMed
Koopmanschap, M.A., Rutten, F.F.H., Van Ineveld, B.M., Van Roijen, L.The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171–189.CrossRefGoogle ScholarPubMed
Nienhuis, FJ, Wunderink, L, Sytema, S, Wiersma, D.Feasibility of targeted treatment in remitted first episode psychosis. Acta Psychiatrica Scandinavica, submitted for publication.Google Scholar
Oostenbrink, J.B., Koopmanschap, M.A., Rutten, F.F.H.Manual for cost studies, methods and standard prices for economic evaluation in health care [In Dutch: Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie]. Amstelveen: Health Care Insurance Council; 2004.Google Scholar
Stant, A.D., TenVergert, E.M., Groen, H., Jenner, J.A., Nienhuis, F.J., Van de Willige, G.et al.Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations. Acta Psychiatr Scand 2003;107:361–368.CrossRefGoogle ScholarPubMed
Tarricone, R., Gerzeli, S., Montanelli, R., Frattura, L., Percudani, M., Racagni, G.Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000;51:1–18.CrossRefGoogle ScholarPubMed
Weinstein, M.C., Stason, W.B.Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716–721.CrossRefGoogle ScholarPubMed
Wiersma, D., Nienhuis, F.J., Slooff, C.J., Giel, R.Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998;24:75–85.CrossRefGoogle ScholarPubMed
World Health Organization. The world health report 2001. Mental health: new understanding, new hope. Geneva; World Health Organization; 2001.Google Scholar
Wu, E.Q., Birnbaum, H.G., Shi, L., Ball, D.E., Kessler, R.C., Moulis, M.et al.The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122–1129.CrossRefGoogle ScholarPubMed
Wunderink, L, Nienhuis, FJ, Sytema, S, Slooff, CJ, Knegtering, R, Wiersma, D.Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome. J Clin Psychiatry in press.Google Scholar
Wyatt, R.J., Damiani, L.M., Henter, I.D.First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry 1998;172:77–83.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.